Abstract
Efforts to cure diabetes are now focused on restoring a physiologically-regulated population of insulinproducing cells to the patient. A number of animal models of β cell regeneration have been employed to study the mechanisms of the process. Islet neogenesis, the regeneration of pancreatic islets from pancreatic stem cells, is arguably the least fraught with barriers to widespread use as a therapy for diabetes. These animal models have led to the description of the reg family of proteins that appear to be related to islet regeneration. Islet neogenesis-associated protein (INGAP) is an initiator of islet neogenesis in animal models and a peptide sequence from INGAP carries the biological activity. INGAP peptide has been shown to stimulate an increase in β cell mass in mice, rats, hamsters and dogs. INGAP is also found in the pancreas in human pathological states involving islet neogenesis. The peptide has been tested in human clinical trials, with success being reported. The evidence points to INGAP as a major factor in stimulating islet neogenesis, and, therefore, may play a significant therapeutic role in diabetes.
Keywords: Pancreas, islet regeneration, islet neogenesis, reg protein
Current Protein & Peptide Science
Title: The Role of Islet Neogeneis-Associated Protein (INGAP) in Pancreatic Islet Neogenesis
Volume: 10 Issue: 1
Author(s): Gary L. Pittenger, David Taylor-Fishwick and Aaron I. Vinik
Affiliation:
Keywords: Pancreas, islet regeneration, islet neogenesis, reg protein
Abstract: Efforts to cure diabetes are now focused on restoring a physiologically-regulated population of insulinproducing cells to the patient. A number of animal models of β cell regeneration have been employed to study the mechanisms of the process. Islet neogenesis, the regeneration of pancreatic islets from pancreatic stem cells, is arguably the least fraught with barriers to widespread use as a therapy for diabetes. These animal models have led to the description of the reg family of proteins that appear to be related to islet regeneration. Islet neogenesis-associated protein (INGAP) is an initiator of islet neogenesis in animal models and a peptide sequence from INGAP carries the biological activity. INGAP peptide has been shown to stimulate an increase in β cell mass in mice, rats, hamsters and dogs. INGAP is also found in the pancreas in human pathological states involving islet neogenesis. The peptide has been tested in human clinical trials, with success being reported. The evidence points to INGAP as a major factor in stimulating islet neogenesis, and, therefore, may play a significant therapeutic role in diabetes.
Export Options
About this article
Cite this article as:
Pittenger L. Gary, Taylor-Fishwick David and Vinik I. Aaron, The Role of Islet Neogeneis-Associated Protein (INGAP) in Pancreatic Islet Neogenesis, Current Protein & Peptide Science 2009; 10 (1) . https://dx.doi.org/10.2174/138920309787315211
DOI https://dx.doi.org/10.2174/138920309787315211 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Postprandial State and its Influence on the Development of Atherosclerosis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Transmucosal Delivery of Metformin- A Comprehensive Study
Current Drug Delivery Hypolipidemic, Antioxidant and Cardioprotective Effects of the Aqueous Extract from <i>Scorzanera Undulata</i> Tubers in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Is “Leptin Resistance” Another Key Resistance to Manage Type 2 Diabetes?
Current Diabetes Reviews Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?
CNS & Neurological Disorders - Drug Targets Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design Pharmacological Management of Hypertension in the Elderly - Certitudes and Controversies
Current Pharmaceutical Design Benefits of Chinese Medicine Among Patients with Diabetic Foot: An Expert Review from Clinical Studies
Current Vascular Pharmacology Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Physical Disability and Diabetes Mellitus; Qualitative Exploration of Patients’ Perception and Behavior
Current Diabetes Reviews Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Triamcinolone Acetonide Inhibits p38MAPK Activation and Neuronal Apoptosis in Early Diabetic Retinopathy
Current Molecular Medicine A Facile and Economical Method to Synthesize Vildagliptin
Letters in Organic Chemistry Glucose Control and Use of Continuous Glucose Monitoring in the Intensive Care Unit: A Critical Review
Current Diabetes Reviews Patient-Specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases
Current Stem Cell Research & Therapy Stroke and Hypertension: An Appraisal from Pathophysiology to Clinical Practice
Current Vascular Pharmacology Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?
Current Cardiology Reviews Application of NKT Cells in Immunotherapy
Current Immunology Reviews (Discontinued) Perinatal Depression, Fetal Bonding, and Mother-Child Attachment: A Review of the Literature
Current Pediatric Reviews NMDA Pathology and Treatment of Schizophrenia
Current Pharmaceutical Design